Top

Osteoporosis International

Published in:

01-02-2015 | Original Article

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

Authors: C.-C. Lai, W.-S. Chen, D.-M. Chang, Y.-P. Tsao, T.-H. Wu, C.-T. Chou, C.-Y. Tsai

Published in: Osteoporosis International | Issue 2/2015

Abstract

Summary

In patients with systemic lupus erythematosus (SLE), low bone mineral density (BMD) is associated with increased age, prolonged disease, low body mass index (BMI), and overlap with rheumatoid arthritis (RA). Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin.

Introduction

The objective of this study was to investigate the steroid and CsA effect on bone metabolism and serum FGF-23 in SLE patients.

Methods

Seventy-two SLE patients and 10 age- and sex-matched healthy individuals underwent blood tests for bone metabolic biomarkers and FGF-23, and lumbar spine dual-energy X-ray absorptiometry for BMD.

Results

Comparisons between patients and controls were made in premenopausal women/men younger than 50 years and postmenopausal women/men older than 50 years separately. SLE patients had more frequent low Z-score (≤ − 2.0, 8.5 vs. 0 %), osteopenia (−2.5 < T-score < −1.0, 52 vs. 50 %), and osteoporosis (T-score ≤ −2.5, 12 vs. 0 %), than the healthy age-compatible counterparts. BMD was significantly lower in patients with advanced age, longer disease duration, lower BMI, and overlap with RA (all p < 0.05 by multiple linear regression analyses). Serum FGF-23 was significantly higher and 1,25-dihydroxyvitamin D (1,25(OH)₂D₃) lower in SLE patients treated with glucocorticoid and CsA than in those not taking both of them (p = 0.027 and 0.002, respectively). The cumulative dose of glucocorticoid was inversely correlated with serum intact parathyroid hormone (r = −0.299, p = 0.011), C-terminal telopeptide of type I collagen (r = −0.581, p < 0.001), and osteocalcin (r = −0.648, p < 0.001). FGF-23 and the cumulative dose of CsA were positively correlated (r = 0.38, p = 0.001) and both were negatively correlated with 1,25(OH)₂D₃ (r = −0.266, p = 0.016 and r = −0.55, p < 0.001) and osteocalcin (r = −0.234, p = 0.034 and r = −0.274, p = 0.02).

Conclusion

SLE patients treated with glucocorticoid and CsA exhibited markedly decreased bone turnover. Those taking CsA had higher serum FGF-23 associated with suppression of 1,25(OH)₂D₃ and bone formation. Such high-risk patients necessitate regular screening of osteoporosis.

Movsowitz C, Epstein S, Ismail F, Fallon M, Thomas S (1989) Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption. J Bone Miner Res 4:393–398PubMedCrossRef

Lane NE, Lukert B (1998) The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27:465–483PubMedCrossRef

Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H (2005) NFAT and Osterix cooperatively regulate bone formation. Nat Med 11:880–885PubMedCrossRef

van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389CrossRef

Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, de Vries F (2014) Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 25:1275–1283PubMedCrossRef

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568PubMedCentralPubMedCrossRef

Baum M, Schiavi S, Dwarakanath V, Quigley R (2005) Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 68:1148–1153PubMedCrossRef

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435PubMedCrossRef

Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131PubMedCrossRef

10.

Celik E, Guzel S, Abali R, Guzelant AY, Celik Guzel E, Kuçukyalcin V (2013) The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women. Minerva Med 104:497–504PubMed

11.

Mirza MA, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Ljunggren O, Larsson TE (2011) Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 26:857–864PubMedCrossRef

12.

Toloza SM, Cole DE, Gladman DD, Ibañez D, Urowitz MB (2010) Vitamin D insufficiency in a large female SLE cohort. Lupus 19:13–19PubMedCrossRef

13.

Souto M, Coelho A, Guo C, Mendonca L, Argolo S, Papi J, Farias M (2011) Vitamin D insufficiency in Brazilian patients with SLE: prevalence, associated factors, and relationship with activity. Lupus 20:1019–1026PubMedCrossRef

14.

Chaiamnuay S, Chailurkit LO, Narongroeknawin P, Asavatanabodee P, Laohajaroensombat S, Chaiamnuay P (2013) Current daily glucocorticoid use and serum creatinine levels are associated with lower 25(OH) vitamin D levels in Thai patients with systemic lupus erythematosus. J Clin Rheumatol 19:121–125PubMedCrossRef

15.

Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF, Voskuyl AE, Bultink IE (2013) Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 24:1827–1833PubMedCrossRef

16.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef

17.

Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef

18.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef

19.

Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 16:455–466PubMedCrossRef

20.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMedCentralPubMedCrossRef

21.

Young A, Hodsman AB, Boudville N, Geddes C, Gill J, Goltzman D, Jassal SV, Klarenbach S, Knoll G, Muirhead N et al (2012) Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis 59:761–769PubMedCrossRef

22.

Lee JJ, Aghdassi E, Cheung AM, Morrison S, Cymet A, Peeva V, Neville C, Hewitt S, DaCosta D, Pineau C et al (2012) Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. J Rheumatol 39:1378–1384PubMedCrossRef

23.

Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13:436–441PubMedCrossRef

24.

Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escárcega RO, Jiménez-Hernández M, Etchegaray-Morales I, Soto-Vega E, Muñoz-Guarneros M, López-Colombo A, Delezé-Hinojosa M et al (2009) Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol 28:65–70PubMedCrossRef

25.

Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah S, Chow SK, Goh EM (2009) Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids. Lupus 18:178–181PubMedCrossRef

26.

Furukawa M, Kiyohara C, Tsukamoto H, Mitoma H, Kimoto Y, Uchino A, Nakagawa M, Oryoji K, Shimoda T, Akashi K et al (2011) Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus. Rheumatol Int 31:365–376PubMedCrossRef

27.

Souto MI, Coelho A, Guo C, Mendonca LM, Pinheiro MF, Papi JA, Farias ML (2012) The prevalence of low bone mineral density in Brazilian patients with systemic lupus erythematosus and its relationship with the disease damage index and other associated factors. J Clin Densitom 15:320–327PubMedCrossRef

28.

Li EK, Tam LS, Young RP, Ko GT, Li M, Lau EM (1998) Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. Br J Rheumatol 37:405–410PubMedCrossRef

29.

Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28:102–108PubMed

30.

Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED (2007) Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 56:1966–1973PubMedCrossRef

31.

Sandhu SK, Hampson G (2011) The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol 64:1042–1050PubMedCrossRef

32.

Mok CC (2013) Vitamin D and systemic lupus erythematosus: an update. Expert Rev Clin Immunol 9:453–463PubMedCrossRef

33.

Baker-LePain JC, Nakamura MC, Shepherd J, von Scheven E (2011) Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) 50:611–619CrossRef

34.

Banno S, Matsumoto Y, Naniwa T, Hayami Y, Sugiura Y, Yoshinouchi T, Ueda R (2002) Reduced bone mineral density in Japanese premenopausal women with systemic lupus erythematosus treated with glucocorticoids. Mod Rheumatol 12:323–328PubMedCrossRef

35.

Yeo H, McDonald JM, Zayzafoon M (2006) NFATc1: a novel anabolic therapeutic target for osteoporosis. Ann N Y Acad Sci 1068:564–567PubMedCrossRef

36.

O’Regan S, Chesney RW, Hamstra A, Eisman JA, O’Gorman AM, Deluca HF (1979) Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 68:109–111PubMedCrossRef

37.

Lee CT, Ng HY, Lien YH, Lai LW, Wu MS, Lin CR, Chen HC (2011) Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol 34:87–94PubMedCrossRef

38.

Kovalik M, Mellanby RJ, Evans H, Berry J, van den Broek AH, Thoday KL (2012) Ciclosporin therapy is associated with minimal changes in calcium metabolism in dogs with atopic dermatitis. Vet Dermatol 23:481–e491PubMedCrossRef

39.

Gesek FA, Friedman PA (1992) On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 90:749–758PubMedCentralPubMedCrossRef

40.

Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793–1803PubMedCrossRef

41.

Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE (2012) FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 7:727–734PubMedCentralPubMedCrossRef

42.

Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, Shalhoub V, Mohammadi M, Pohl EE, Lanske B et al (2014) FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 33:229–246PubMedCentralPubMed

43.

Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L et al (2012) Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 14:R221PubMedCentralPubMedCrossRef

44.

Abou-Raya A, Abou-Raya S, Helmii M (2013) The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol 40:265–272PubMedCrossRef

45.

Austin HA 3rd, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20:901–911PubMedCentralPubMedCrossRef

Title: Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only
Authors: C.-C. Lai
W.-S. Chen
D.-M. Chang
Y.-P. Tsao
T.-H. Wu
C.-T. Chou
C.-Y. Tsai
Publication date: 01-02-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 2/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2910-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports

Reproducibility of jumping mechanography and traditional measures of physical and muscle function in older adults

The interactions between municipal socioeconomic status and age on hip fracture risk

Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial

Validation of a short questionnaire for estimating dietary calcium intakes

Minimal-trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis